SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals
ARIA 23.990.0%Feb 17 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: trading_cyclist who wrote (4097)2/1/2016 6:29:09 PM
From: Vidpok1  Read Replies (2) of 4474
 
TC although 788 is years away from profitability, as Jaybe said there is likely a large population which may benefit from it and this won't go unnoticed by BP. For the purposes of establishing a buyout price 788 should have a substantial impact if the drug may be used for an unmet need by over 20,000 people. You can imagine Denner's arguments for bic 113 as well as the potential for ponatinib and 788 in negotiating the buyout. I think some may be surprised at the premium we achieve which I still believe will be in the high teens despite our current malaise which is mostly a function of the biotech correction.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News